BiotechTube
Cook MyoSite

Cook MyoSite

Pittsburgh, United States· Est.
cookmyosite.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cook MyoSite is a private, clinical-stage biotech leveraging over 20 years of expertise in muscle cell technology to develop regenerative therapies. Its core asset is iltamiocel, an autologous muscle-derived cell therapy with FDA RMAT designation, currently in Phase III trials for stress urinary incontinence and fecal incontinence, and Phase II/III for oropharyngeal dysphagia. The company also generates early revenue through a Laboratory Research Services division, offering characterized primary cells and custom services to the research community under an ISO9001-certified quality system.

UrologyGastroenterologyOtolaryngology

Technology Platform

Autologous muscle-derived cell (AMDC) platform for isolating, expanding, and re-implanting a patient's own muscle progenitor cells (iltamiocel) to restore function in damaged or dysfunctional muscle tissue.

Opportunities

The lead programs target large, underserved patient populations with high unmet need, such as women with post-surgical stress urinary incontinence and fecal incontinence, representing multi-billion dollar market opportunities.
FDA RMAT designation for all programs can accelerate development and review timelines, providing a potential first-mover advantage in muscle-derived cell therapies.

Risk Factors

The company faces significant clinical risk as its valuation hinges on positive Phase III trial results for iltamiocel.
Commercialization presents major challenges, including establishing scalable autologous manufacturing, securing reimbursement, and driving adoption of a complex, personalized cell therapy.
Competition from other regenerative medicine approaches and established medical device companies poses a long-term threat.

Competitive Landscape

Cook MyoSite is a niche player focusing specifically on autologous muscle-derived cells. It faces potential competition from companies developing allogeneic stem cell therapies, tissue-engineered implants, and neuromodulation devices for incontinence. In dysphagia, competition is less defined, offering a potential first-to-market opportunity. Its deep, specialized expertise in muscle cell biology is a key differentiator.

More companies in Cell & Gene Therapy →More companies in United States →